← Back to Screener
Supernus Pharmaceuticals, Inc. (SUPN)
Price$51.25
Favorite Metrics
Price vs S&P 500 (26W)-3.87%
Price vs S&P 500 (4W)-1.89%
Market Capitalization$2.92B
P/E Ratio (Annual)43.28x
All Metrics
P/CF (Annual)61.70x
Book Value / Share (Quarterly)$18.48
P/TBV (Annual)5.79x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.52%
Cash Flow / Share (Quarterly)$0.80
Price vs S&P 500 (YTD)-0.74%
Gross Margin (TTM)89.89%
Net Profit Margin (TTM)-5.36%
EPS (TTM)$-0.68
10-Day Avg Trading Volume0.53M
EPS Excl Extra (TTM)$-0.68
Revenue Growth (5Y)6.68%
EPS (Annual)$-0.68
ROI (Annual)-3.63%
Gross Margin (Annual)89.89%
Net Profit Margin (5Y Avg)4.87%
Cash / Share (Quarterly)$5.37
Revenue Growth QoQ (YoY)21.48%
EPS Growth (5Y)-8.89%
P/E Normalized (Annual)43.28x
ROA (Last FY)-2.65%
Revenue Growth TTM (YoY)8.63%
EBITD / Share (TTM)$0.48
ROE (5Y Avg)3.41%
Operating Margin (TTM)-8.66%
Cash Flow / Share (Annual)$0.80
P/B Ratio2.75x
P/B Ratio (Quarterly)2.68x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.88x
Net Interest Coverage (TTM)9.04x
ROA (TTM)-2.75%
EV / EBITDA (TTM)102.75x
EPS Incl Extra (Annual)$-0.68
Current Ratio (Annual)1.90x
Quick Ratio (Quarterly)1.47x
3-Month Avg Trading Volume0.69M
52-Week Price Return67.34%
EV / Free Cash Flow (Annual)60.71x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$8.57
P/S Ratio (Annual)4.06x
Asset Turnover (Annual)0.49x
52-Week High$59.68
Operating Margin (5Y Avg)4.91%
EPS Excl Extra (Annual)$-0.68
CapEx CAGR (5Y)-17.02%
Tangible BV CAGR (5Y)5.28%
26-Week Price Return4.88%
Quick Ratio (Annual)1.47x
13-Week Price Return-0.79%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.90x
Enterprise Value$2,792.096
Revenue / Share Growth (5Y)5.62%
Asset Turnover (TTM)0.51x
Book Value / Share Growth (5Y)5.59%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.06x
Pretax Margin (Annual)-6.82%
Cash / Share (Annual)$5.37
3-Month Return Std Dev32.78%
Gross Margin (5Y Avg)87.93%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)-31.86%
EBITDA Interim CAGR (5Y)-14.44%
ROE (Last FY)-3.63%
Net Interest Coverage (Annual)8.96x
EPS Basic Excl Extra (Annual)$-0.68
P/FCF (TTM)27.10x
Receivables Turnover (TTM)4.36x
EV / Free Cash Flow (TTM)60.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.68
Receivables Turnover (Annual)4.36x
ROI (TTM)-3.67%
P/S Ratio (TTM)4.06x
Pretax Margin (5Y Avg)6.03%
Revenue / Share (Annual)$12.74
Tangible BV / Share (Annual)$8.57
Forward P/E26.69x
Free OCF CAGR (5Y)-19.37%
Price vs S&P 500 (52W)32.24%
Year-to-Date Return3.40%
5-Day Price Return2.88%
EPS Normalized (Annual)$-0.68
ROA (5Y Avg)1.92%
Net Profit Margin (Annual)-5.36%
Month-to-Date Return-0.58%
Cash Flow / Share (TTM)$1.89
EBITD / Share (Annual)$0.48
EPS Growth (3Y)10.38%
Operating Margin (Annual)-8.66%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)61.70x
ROI (5Y Avg)2.56%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.68
P/TBV (Quarterly)5.79x
P/B Ratio (Annual)2.68x
Inventory Turnover (TTM)1.06x
Pretax Margin (TTM)-6.82%
Book Value / Share (Annual)$18.48
Price vs S&P 500 (13W)-3.66%
Net Margin Growth (5Y)-17.27%
Beta0.64x
P/FCF (Annual)63.50x
Revenue / Share (TTM)$12.52
ROE (TTM)-3.67%
52-Week Low$29.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SUPNSupernus Pharmaceuticals, Inc. | 4.06x | 8.63% | 89.89% | -8.89% | $51.25 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system disorders, including neurological and psychiatric conditions. Its portfolio of eight marketed products addresses key indications such as epilepsy, migraine, ADHD, Parkinson's disease complications, and dystonia. The company serves underserved patient populations within the neuroscience space.